3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Solid Tumor
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
31
Trastuzumab
30
Paclitaxel
28
Docetaxel
22
Taxes
18
Doxorubicin
18
Lapatinib
15
Radiotherapy
14
Capecitabine
14
Bevacizumab
13
Tamoxifen
12
Carboplatin
11
Filgrastim
9
sargramostim
8
Granulocyte-Macrophage Colony-Stimulating Factor
8
Chemotherapy, Adjuvant
8
exemestane
7
Vorinostat
7
Letrozole
7
Immunohistochemistry
7
Gemcitabine
7
Anastrozole
7
Albumin-Bound Paclitaxel
7
pegfilgrastim
6
Neoadjuvant Therapy
6
Magnetic Resonance Spectroscopy
6
Immunoenzyme Techniques
6
Goserelin
6
Flow Cytometry
6
Everolimus
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms, Male
×
seviteronel
×
Clear all
NCT02580448
2019-02-01
CLARITY-01
Innocrin Pharmaceutical
Phase 1/2
Completed
175 enrolled